Clinical trials: High Risk Localized Prostate Cancer, active
Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
This clinical trial evaluates the use of an imaging scan (18F-rhPSMA-7.3 positron emission tomography [PET]/magnetic resonance imaging [MRI]) for identifying patients who are at risk of having their disease spread to the lymph…
- Conditions
- Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT06389786
- Testing
- Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Localized Prostate Cancer, BPH (Benign Prostatic Hyperplasia)
Sonablate HIFU International Registry for PC & BPH Patients
The SONA FUSION Registry is an observational study designed to evaluate the long-term effectiveness and safety of the Sonablate High-Intensity Focused Ultrasound (HIFU) system.
- Conditions
- Localized Prostate Cancer, BPH (Benign Prostatic Hyperplasia), Prostate Cancer; Benign Prostatic Hyperplasia
- Trial name
- SONAFUSION (NCT07757490)
- Testing
- High Intensity Focused Ultrasound
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Sonablate
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Prostate Cancer
Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)
This is a multicenter observational study of patients undergoing focal therapy for prostate cancer in Asia
- Trial name
- ProAMFocal (NCT06491056)
- Testing
- Focal Therapy for Prostate Cancer
- Where
- Singapore
- Volunteers
- 500 people
- Sponsor
- Singapore General Hospital
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment.
- Conditions
- Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
- Trial name
- ARPEGGIO (NCT07393867)
- Testing
- PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Martin T. King, MD, PhD
Prostate Cancer
High Intensity Focused Ultrasound in Prostate Cancer
This study will investigate the efficacy of focal high intensity focused ultrasound (HIFU) in patients with localized radiorecurrent prostate cancer.
- Trial name
- NCT06402357
- Testing
- Focal One high intensity focused ultrasound device
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Florida
Prostate Cancer, Localized Prostate Carcinoma
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT.
- Trial name
- NCT07455903
- Testing
- Leuprolide, Degarelix, Relugolix
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baptist Health South Florida
Prostate CA, Prostate Cancer (Adenocarcinoma)
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
The goal of this clinical trial is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa) in…
- Conditions
- Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery
- Trial name
- NCT06631521
- Testing
- Darolutamide, Relugolix, Radical Prostatectomy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AdventHealth
Prostate Cancer, Prostate Adenocarcinoma
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, simultaneous integrated boost (SIB) to the prostate…
- Trial name
- NCT04486755
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Maryland, Baltimore
Prostate Cancer
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
This study is a single-arm prospective cohort study designed to evaluate the efficacy and safety of triple therapy (ADT + darolutamide + docetaxel) combined with transrectal high-intensity focused ultrasound (HIFU) focal therapy…
- Trial name
- NCT07172685
- Testing
- Darolutamide , Docetaxel , ADT and Transrectal HIFU Focal Therapy
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Qilu Hospital of Shandong University
Prostate Cancer
Pembro With Radiation With or Without Olaparib
This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized…
- Trial name
- NCT05568550
- Testing
- Pembrolizumab, Olaparib, Androgen Deprivation Therapy
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Zin W Myint
Male Erectile Disorder, Prostate Cancer
Focal Therapy for Prostate Cancer Using HIFU
RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men…
- Conditions
- Male Erectile Disorder, Prostate Cancer, Therapy-related Toxicity, Urinary Incontinence
- Trial name
- INDEX (NCT01194648)
- Testing
- questionnaire administration, assessment of therapy complications, high-intensity focused ultrasound ablation
- Where
- United Kingdom
- Volunteers
- 354 people
- Sponsor
- University College, London
Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis)
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI…
- Trial name
- ECETEP (NCT07766122)
- Testing
- Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
High-risk Localized Prostate Cancer
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
Researchers are looking for a better way to treat men who have high-risk localized prostate cancer, which refers to a type of prostate cancer that is still confined to the prostate gland but has certain characteristics that make…
- Trial name
- CHINANEO (NCT07450599)
- Testing
- Darolutamide, ADT
- Where
- 23 sites in China
- Volunteers
- 250 people
- Sponsor
- Bayer
Localized Prostate Cancer
Focal Micro-boost Strategy in Patients With Intermediate- to High-risk Prostate Cancer (IR-HR PCa) Undergoing Hypofractionated Radiotherapy
HYPO62 SPECIAL is a monocentric, prospective observational cohort study promoted by IFO-IRE/ISG, designed to evaluate a moderately hypofractionated radiotherapy strategy with focal micro-boost in patients with localized…
- Trial name
- 62SPECIAL (NCT07792993)
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Regina Elena Cancer Institute
Prostate Cancer, Prostate Cancer (Diagnosis)
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy.
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma
- Trial name
- LUTACT (NCT07054346)
- Testing
- 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Thomas Hope
PROSTATE CANCER, NERVES
Periprostatic Neurolysis in Prostate Cancer
The purpose of this research study is to assess whether inhibiting nerve activity to the prostate delays progression of disease in men with high-risk clinical features for prostate cancer.
- Conditions
- PROSTATE CANCER, NERVES, NEUROBIOLOGY OF CANCER, NEUROLYSIS
- Trial name
- NCT07100847
- Testing
- Periprostatic neurolysis with dehydrated alcohol (ethanol)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy.
- Trial name
- HEAT (NCT06014255)
- Testing
- Enoblituzumab, Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 219 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer
A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound…
- Trial name
- TACT (NCT02766543)
- Testing
- MRI-guided Transurethral Ultrasound Ablation
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 150 people
- Sponsor
- Profound Medical Inc.
Prostate Cancer
Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate
In this study, participants will have standard Androgen Deprivation Therapy and undergo standard external beam radiation therapy to the prostate and at-risk lymph nodes by Intensity Modulated Radiation Therapy.
- Trial name
- NCT01508390
- Testing
- CyberKnife Boost
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Boston Medical Center